[Therapy and prevention of pneumocystis carinii pneumonia].
Goebel
F D
FD
Medizinische Poliklinik, Klinikum Innenstadt, Ludwig-Maximilians-Universität, München.
Bogner
J R
JR
D017088:AIDS-Related Opportunistic Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D000818:Animals; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D053626:Atovaquone; D002981:Clindamycin / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003622:Dapsone / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D009285:Naphthoquinones / Q000009:adverse effects / Q000627:therapeutic use; D010419:Pentamidine / Q000009:adverse effects / Q000627:therapeutic use; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis / Q000188:drug therapy* / Q000517:prevention & control; D011319:Primaquine / Q000009:adverse effects / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use
D000935:Antifungal Agents; D009285:Naphthoquinones; D002981:Clindamycin; D010419:Pentamidine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D003622:Dapsone; D011319:Primaquine; D053626:Atovaquone
Therapie und Prophylaxe der Pneumocystis-carinii-Pneumonie.